ARS Pharmaceuticals (SPRY) EBIAT (2020 - 2026)
ARS Pharmaceuticals recorded quarterly EBIAT of -$60.6 million in Q1 2026, down 46.69% quarter-over-quarter from -$41.3 million in Q4 2025, and down 78.6% year-over-year from -$283.3 million in Q1 2025.
ARS Pharmaceuticals' EBIAT history runs 7 years deep, the most recent figure standing at -$60.6 million for Q1 2026.
- In Q1 2026, EBIAT fell 78.6% year-over-year to -$60.6 million; the TTM figure through Mar 2026 stood at -$198.0 million (down 1165.02% YoY), while the FY2025 annual figure was -$171.3 million, down 2241.76% from the prior year.
- EBIAT came in at -$60.6 million for Q1 2026 at ARS Pharmaceuticals, down from -$41.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $49.9 million in Q4 2024 to a low of -$60.6 million in Q1 2026.
- A 5-year average of -$18.4 million and a median of -$14.9 million in 2023 frame the typical range for EBIAT.
- Across the five-year window, EBIAT soared 796.62% in 2024 and plunged 258.6% in 2025, its largest moves.
- ARS Pharmaceuticals' EBIAT stood at -$14.4 million in 2022, then jumped by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then sank by 182.76% to -$41.3 million in 2025, then slumped by 46.69% to -$60.6 million in 2026.
- According to Business Quant data, EBIAT over the past three periods registered -$60.6 million, -$41.3 million, and -$51.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -60.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.62 Mn |
| Dec 31, 2025 | -41.32 Mn |
| Sep 30, 2025 | -51.15 Mn |
| Jun 30, 2025 | -44.88 Mn |
| Mar 31, 2025 | -33.94 Mn |
| Dec 31, 2024 | 49.93 Mn |
| Sep 30, 2024 | -19.13 Mn |
| Jun 30, 2024 | -12.52 Mn |
| Mar 31, 2024 | -10.29 Mn |
| Dec 31, 2023 | -7.17 Mn |
| Sep 30, 2023 | -14.87 Mn |
| Jun 30, 2023 | -17.37 Mn |
| Mar 31, 2023 | -14.96 Mn |
| Dec 31, 2022 | -14.43 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -6.42 Mn |
| Mar 31, 2022 | -7.25 Mn |
| Dec 31, 2021 | 45.78 Mn |
| Sep 30, 2021 | -22.66 Mn |
| Jun 30, 2021 | -24.50 Mn |
| Mar 31, 2021 | -18.87 Mn |
| Dec 31, 2020 | -13.09 Mn |
| Sep 30, 2020 | -8.12 Mn |
| Jun 30, 2020 | -6.47 Mn |
| Mar 31, 2020 | -5.28 Mn |